Biotech Gainers: Inovio Pharmaceuticals Inc (NYSEMKT:INO), Northwest Biotherapeutics (NASDAQ:NWBO), Peregrine Pharmaceuticals (NASDAQ:PPHM), Dyax (NASDAQ:DYAX)

Trade-Ideas LLC identified Inovio Pharmaceuticals Inc (NYSEMKT:INO) as a “barbarian at the gate” (strong stocks crossing above resistance with today’s range greater than 200%) candidate. Inovio Pharmaceuticals, Inc. (NYSEMKT:INO), together with its subsidiaries, engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. Currently there are 3 analysts that rate Inovio Pharmaceuticals Inc (NYSEMKT:INO) a buy, no analysts rate it a sell, and none rate it a hold. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was 12.69% in last session and finished the day at $3.64. Traded volume was 17.44million shares in the last session and the average volume of the stock remained 7.60million shares. The beta of the stock remained 3.55. Inovio Pharmaceuticals Inc (NYSEMKT:INO) insider ownership is 0.30%.

HealthBank is run by Northwest Biotherapeutics Inc (NASDAQ:NWBO), a publicly traded cancer immunotherapy company based in Bethesda, Md. It charges $2,000 for processing and a year of storage, plus $195 for each subsequent year (about $16 a month). Northwest Biotherapeutics, Inc (NASDAQ:NWBO) rose 15.09 percent to $7.78 Thursday on volume of 3.19million shares. The intra-day range of the stock was $6.90 to $8.09. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) has a market capitalization of $337.68million.

Shares of Peregrine Pharmaceuticals (NASDAQ:PPHM) were the target of a significant growth in short interest in the month of January. As of March 14th, there was short interest totaling 15,610,186 shares, a growth of 51.8% from the February 28th total of 10,280,960 shares, Stock Ratings News reports. Peregrine Pharmaceuticals (NASDAQ:PPHM)’s stock on Mar 27, 2014 reported a increase of 5.41% to the closing price of $1.95. Its fifty two weeks range is $1.11 -$3.18. The total market capitalization recorded $344.14million. The overall volume in the last trading session was 3.07million shares. In its share capital, PPHM has 163.22million outstanding shares.

Trade-Ideas LLC identified Dyax Corporation (NASDAQ:DYAX) as a “dead cat bounce” (down big yesterday but up big today) candidate. Dyax Corp. (NASDAQ:DYAX), a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and plasma kallikrein-mediated (PKM) angioedemas. The company offers KALBITOR for the treatment of acute attacks of HAE. On Thursday, shares of Dyax Corp. (NASDAQ:DYAX) advanced 5.19% to close the day at $8.71. Company return on investment (ROI) is -15.80% and its monthly performance is recorded as -19.50%. Dyax Corp. (NASDAQ:DYAX) quarterly revenue growth is 13.41%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone